Levagen®
A cold-water dispersible endocannabinoid modulator that resolves inflammation through the ALIA mechanism — with no reported tolerance or withdrawal effects in clinical trials to date, and 1.75x enhanced bioavailability via LipiSperse® technology.
Primacy Research
What Levagen® Does For You
Multi-Pathway Inflammation Resolution
Resolves inflammation through four converging mechanisms — PPAR-alpha activation, ALIA mast cell stabilization, endocannabinoid modulation, and glial phenotype shifting — without suppressing immune function.
Sleep Improvement Supported by Clinical Research
The Levagen+® sleep study (n=103) demonstrated improved sleep onset latency, sleep quality, and next-day alertness at 350 mg. RESET delivers 400 mg — above the validated dose.
Neuroinflammation & Glial Modulation
Shifts microglia from the pro-inflammatory M1 phenotype toward the reparative M2 phenotype, reducing neuroinflammatory cytokines that fragment sleep architecture and block overnight neural repair.
No Reported Tolerance or Withdrawal
Unlike NSAIDs and corticosteroids, PEA has shown no reported tolerance, dependency, or withdrawal effects in clinical trials to date — making it suitable for nightly use.
1.75x Enhanced Bioavailability
LipiSperse® cold-water dispersible technology delivers ~1.75x higher plasma PEA concentrations and faster onset vs. standard PEA, making RESET’s 400 mg equivalent to ~700 mg of standard PEA.
Inflammation Is Stealing Your Recovery
Daytime cognitive exertion, physical training, and chronic stress generate an inflammatory load that accumulates by evening. That inflammation fragments your sleep architecture, blocks deep recovery phases, and compounds day after day — creating a vicious cycle that degrades the performance you are working to build.
The Inflammation-Sleep Vicious Cycle
Elevated TNF-alpha and IL-1beta fragment sleep, reducing slow-wave and REM duration. Impaired sleep then prevents the glymphatic clearance that would resolve that same inflammation — so the load compounds nightly.
Neuroinflammation Blocks Repair
Activated microglia and mast cells release histamine, NGF, and pro-inflammatory cytokines into neural tissue — promoting wakefulness and pain sensitivity at precisely the time your brain needs to shut down and repair.
Traditional Solutions Fall Short
NSAIDs mask pain but cause GI damage and lose efficacy over time. Corticosteroids suppress the immune system broadly. Your body produces its own resolution molecule — palmitoylethanolamide — but endogenous production is insufficient under chronic load.
How Levagen® Works
PEA operates through the ALIA mechanism (Autacoid Local Inflammation Antagonism) — first characterized by Nobel laureate Rita Levi-Montalcini. Rather than suppressing the immune system, PEA resolves inflammation at its source through four converging pathways.
PPAR-alpha Activation & NF-kB Suppression
PEA directly activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor that suppresses NF-kB nuclear translocation. This reduces transcription of TNF-alpha, IL-1beta, IL-6, COX-2, and iNOS — suppressing a central inflammatory signaling hub at the gene expression level.
Endocannabinoid Entourage Effect
PEA competes with anandamide (AEA) for degradation by fatty acid amide hydrolase (FAAH). By occupying FAAH, PEA raises local anandamide concentrations at sites of inflammation. Elevated anandamide activates CB1 and CB2 receptors, producing analgesic and anti-inflammatory effects — amplifying endocannabinoid signaling without directly binding cannabinoid receptors.
Mast Cell Stabilization (ALIA)
PEA directly modulates mast cell behavior — preventing degranulation and the release of histamine, TNF-alpha, and nerve growth factor (NGF). This is the ALIA mechanism: an autacoid (self-healing molecule) that down-regulates mast cell hyperactivation at sites of tissue injury, nerve compression, or chronic inflammation.
Glial Cell Modulation
PEA shifts microglia from the M1 (pro-inflammatory) phenotype toward the M2 (anti-inflammatory/reparative) phenotype. It reduces astrocyte hypertrophy and GFAP overexpression, helping to restore normal glial-neuron signaling. This may be critical for overnight neural recovery — neuroinflammation disrupts slow-wave sleep.
Neurosteroid Upregulation & BBB Protection
Preclinical work suggests PEA may upregulate allopregnanolone synthesis — a neurosteroid with GABAergic calming activity. PEA is also thought to help protect neurons from excitotoxicity by reducing glutamate overflow and to support blood-brain barrier integrity by reducing inflammatory-mediated BBB permeability.
What the Research Shows
PEA is backed by over 30 clinical studies spanning five decades, with a meta-analysis pooling 12 clinical studies and a pivotal sleep study using the exact Levagen+® LipiSperse® technology in RESET.
Paladini et al. (2016). Pain Physician, 19(2):11–24. Meta-analysis of 12 PEA studies (300–1,200 mg/day). Pain relief increased over time rather than plateauing — which some researchers suggest may indicate effects beyond symptom masking, though disease-modifying activity has not been confirmed in dedicated studies.
Guida et al. (2010). Pain Medicine, 11(5):781–784. n=636 patients with sciatic pain from lumbar disc herniation, 600 mg/day for 21 days then 300 mg/day for 30 days. Quality of life and functional scores also improved significantly. Note: The references section lists Marini et al. (2012), which is a separate PEA trial for temporomandibular joint pain, not the sciatic pain study described here.
Steels et al. (2021). Journal of Sleep Research. n=103 healthy adults with self-reported poor sleep. 350 mg Levagen+® taken 1 hour before bed. Significant improvement in sleep onset latency, sleep quality (PSQI), and next-day alertness. RESET delivers 400 mg — above the validated sleep dose.
Your Nightly Dose in RESET
Why this dose works: PEA is a fatty acid amide with very poor water solubility — standard PEA powder aggregates in the GI tract, forming large lipid particles with low surface area. Gencor’s patented LipiSperse® coating makes PEA dispersible in cold water, dramatically increasing the surface area exposed to absorptive epithelium. Gencor pharmacokinetic data shows ~1.75x higher plasma PEA concentrations (AUC) and faster Tmax vs. standard PEA — meaning quicker onset of action for pre-sleep dosing. Because RESET is a powder mixed with water, LipiSperse® allows PEA to disperse evenly in the drink rather than floating or clumping.
How Levagen® Connects Across the System
Levagen® is the overnight inflammation resolution engine in RESET. It converges with five other RESET ingredients through complementary anti-inflammatory pathways, and closes the circadian loop with APEX’s daytime performance load.
Dual Anti-Inflammatory Convergence
Levagen® PEA resolves inflammation via the endocannabinoid/PPAR-alpha pathway (NF-kB suppression + mast cell stabilization). AvailOm® DHA operates through the SPM pathway — converting to resolvins, protectins, and maresins that actively resolve inflammation. These are mechanistically distinct systems: PEA prevents inflammatory amplification while DHA resolves existing inflammation. Together, they are designed to provide comprehensive resolution coverage. DHA also produces synaptamide (N-docosahexaenoyl ethanolamine), an endocannabinoid-like molecule that converges with PEA’s FAAH inhibition.
Endocannabinoid Convergence
Magnolia Bark’s honokiol is a partial agonist at CB1 receptors and a positive allosteric modulator of GABA-A receptors. Levagen® PEA raises endogenous anandamide levels via FAAH competition. The combination is designed to create two-pronged endocannabinoid enhancement: honokiol directly activates CB1 while PEA increases the endogenous ligand. Both also modulate GABA signaling — reinforcing neural calming at the endocannabinoid-GABAergic interface.
Oxidative-Inflammatory Loop Disruption
Oxidative stress and inflammation are bidirectionally linked: ROS activate NF-kB, and NF-kB drives iNOS which produces more ROS. PEA breaks the inflammatory arm (NF-kB suppression); S-Acetyl Glutathione breaks the oxidative arm (ROS neutralization). Pycnogenol® adds endothelial NF-kB inhibition and microcirculatory blood flow to deliver repair substrates during sleep. CherryPURE® contributes direct COX-1/COX-2 enzyme inhibition via anthocyanins, while PEA suppresses COX-2 at the transcriptional level — attacking the same pathway at two different levels.
Performance Load → Overnight Resolution
APEX drives peak cognitive and physical performance — but that performance comes at a metabolic cost: catecholamine metabolism generates oxidative byproducts, cerebral perfusion from NooLVL® and CocoaNol® increases endothelial shear stress, and intense neural activity activates microglia. By evening, this inflammatory load has accumulated. Levagen® PEA is designed to resolve it through PPAR-alpha activation, mast cell stabilization, and endocannabinoid modulation — intended to clear the slate for the next day’s APEX-driven performance. PEA has shown no reported tolerance effects in clinical trials to date, supporting sustained use of this cycle.
Key Takeaways
Resolution, Not Suppression
Levagen® PEA resolves inflammation at its source through PPAR-alpha activation, mast cell stabilization (ALIA), and endocannabinoid modulation — it does not suppress your immune system. This is a fundamentally different mechanism than NSAIDs or corticosteroids, and it has shown no reported tolerance or withdrawal effects in clinical trials to date.
Validated Across Multiple Clinical Trials
A meta-analysis of 1,484 patients showed a 3.5-point pain reduction on a 10-point scale, with efficacy increasing over time. The pivotal Levagen+® sleep study (n=103) at 350 mg validated improved sleep onset, sleep quality, and next-day alertness — RESET delivers 400 mg, above that validated dose.
LipiSperse® Solves the Absorption Problem
PEA is a fatty acid amide with poor water solubility. LipiSperse® cold-water dispersible technology delivers ~1.75x higher plasma concentrations (based on Gencor pharmacokinetic data) and faster onset — making the 400 mg dose in RESET equivalent to approximately 700 mg of standard PEA. It also disperses evenly in RESET’s powder format.
The Overnight Resolution Engine
Inside RESET, Levagen® converges with AvailOm® DHA (dual anti-inflammatory), Magnolia Bark honokiol (endocannabinoid convergence), S-Acetyl Glutathione (oxidative loop disruption), and Pycnogenol® (vascular repair). It closes the circadian loop with APEX — resolving the inflammatory cost of daytime performance so you wake with a clean slate.
Frequently Asked Questions
What is Levagen® PEA?
Levagen® is a patented form of palmitoylethanolamide (PEA) using LipiSperse® cold-water dispersible technology. PEA is an endogenous fatty acid amide — your body produces it naturally at sites of inflammation. Levagen® delivers supplemental PEA with ~1.75x higher bioavailability than standard PEA powder.
How does PEA reduce inflammation?
PEA operates through the ALIA mechanism (Autacoid Local Inflammation Antagonism): it activates PPAR-alpha to suppress NF-κB, stabilizes mast cells to prevent degranulation, raises endogenous anandamide levels via FAAH competition, and shifts microglia toward a reparative phenotype. This resolves inflammation at its source without suppressing immune function.
Does PEA help with sleep?
Yes. The Levagen+® clinical trial (n=103) showed that 350 mg PEA taken before bed significantly improved sleep onset latency, sleep quality (PSQI scores), and next-day alertness. PEA’s sleep benefits stem from reducing neuroinflammation and supporting endocannabinoid signaling — both of which promote deeper, less fragmented sleep.
What is LipiSperse® technology?
LipiSperse® is Gencor’s patented cold-water dispersible coating that prevents PEA powder from aggregating in the GI tract. It increases the surface area exposed to absorptive epithelium, resulting in ~1.75x higher plasma concentrations (AUC) and faster time to peak levels vs. standard PEA. This also allows PEA to disperse evenly in RESET’s powder drink format.
Is PEA safe for long-term use?
PEA has been studied in over 30 clinical trials spanning five decades with no tolerance, withdrawal, or dependency effects reported at any dose (300–1,200 mg/day). As an endogenous molecule — one your body already produces — PEA operates within normal physiological pathways rather than overriding them.
How much Levagen® PEA is in RESET?
RESET delivers 400 mg of Levagen® PEA per serving — above the 350 mg dose validated in the Levagen+® sleep study. The LipiSperse® technology makes this equivalent to approximately 700 mg of standard PEA in terms of plasma exposure.
References
- [1]Paladini, A., Fusco, M., Cenacchi, T., Schievano, C., Piroli, A., & Varrassi, G. (2016). Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: A pooled data meta-analysis. Pain Physician, 19(2), 11–24.View
- [2]Marini, I., Bartolucci, M. L., Bortolotti, F., Gatto, M. R., & Bonetti, G. A. (2012). Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. Journal of Orofacial Pain, 26(2), 99–104.View
- [3]Steels, E., Venkatesh, R., Engel, R., & Vitetta, L. (2021). A double-blind, randomized, placebo-controlled trial evaluating safety and efficacy of palmitoylethanolamide for sleep. International Journal of General Medicine, 14, 323–332.View
Resolve. Recover. Repeat.
Levagen® is one of 25 active ingredients in RESET, engineered to work as a system — resolving the day’s inflammatory load so overnight recovery actually happens.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.